Certified Researchers

Blood Screening Market Summary

As per MRFR analysis, the Blood Screening Market size was valued at USD 3.4 Billion in 2024. The market is projected to grow from USD 3.747 Billion in 2025 to USD 9.898 Billion by 2035, exhibiting a CAGR of 10% during the forecast period 2025-2035. North America led the market with over 45% share, generating around USD 1.5 Billion in revenue.

The Blood Screening Market is expanding due to increasing prevalence of infectious and chronic diseases, rising demand for early disease detection, and growing adoption of advanced screening technologies. Key trends include integration of automated and rapid diagnostic platforms, expanding blood safety programs, and rising government initiatives to enhance healthcare screening infrastructure globally.

According to the World Health Organization, screening for diseases such as HIV, hepatitis B, and hepatitis C is critical to reduce transmission and improve public health outcomes.

Key Market Trends & Highlights

The Blood Screening Market is poised for substantial growth driven by technological advancements and increasing health awareness.

Technological advancements in blood screening are enhancing diagnostic accuracy and efficiency, particularly in North America.
The Asia-Pacific region is emerging as the fastest-growing market, fueled by rising healthcare investments and infrastructure improvements.
Nucleic Acid Amplification Tests dominate the market, while Next-Generation Sequencing is rapidly gaining traction as a preferred method.
Key market drivers include the increasing prevalence of infectious diseases and rising awareness of blood donation and screening initiatives.

Market Size & Forecast

2024 Market Size	3.4 (USD Billion)
2035 Market Size	9.898 (USD Billion)
CAGR (2025 - 2035)	10.2%

Major Players

Companies such as Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Becton Dickinson and Company (US), Ortho Clinical Diagnostics (US), Grifols (ES), Bio-Rad Laboratories (US), Hologic (US) are some of the major participants in the global market.

Our Impact

Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals

Partnering with 2000+ Global Organizations Each Year

30K+ Citations by Top-Tier Firms in the Industry

Blood Screening Market Trends

The Blood Screening Market is currently experiencing a transformative phase, driven by advancements in technology and an increasing emphasis on preventive healthcare. The integration of innovative diagnostic tools and methodologies is reshaping the landscape, allowing for more accurate and efficient detection of blood-borne pathogens and diseases. This evolution is further propelled by rising awareness among healthcare providers and patients regarding the importance of early diagnosis and treatment.

As a result, the market is witnessing a surge in demand for comprehensive blood screening solutions that can cater to diverse healthcare settings, from hospitals to outpatient clinics. Moreover, regulatory frameworks are evolving to support the adoption of new technologies in blood screening. Governments and health organizations are prioritizing the establishment of stringent guidelines to ensure the safety and efficacy of blood screening processes.

This regulatory support, coupled with ongoing research and development efforts, is likely to enhance the overall quality of blood screening services. The Blood Screening Market appears poised for sustained growth, as stakeholders continue to invest in innovative solutions that address the complexities of modern healthcare needs.

The future landscape may be characterized by a greater emphasis on personalized medicine and tailored screening protocols, reflecting the dynamic nature of this vital sector.

Technological Advancements

The Blood Screening Market is witnessing rapid technological innovations that enhance diagnostic accuracy and efficiency. Emerging tools, such as next-generation sequencing and automated analyzers, are streamlining processes and reducing turnaround times. These advancements not only improve patient outcomes but also facilitate the detection of a broader range of pathogens.

According to World Health Organization, innovations such as next-generation sequencing and automated analyzers have improved diagnostic accuracy by over 35% in laboratory settings worldwide.

Regulatory Support

Regulatory bodies are increasingly focusing on establishing robust frameworks to ensure the safety and effectiveness of blood screening practices. This support is crucial for fostering innovation and encouraging the adoption of new technologies. Enhanced regulations may lead to improved standards in testing and quality assurance.

The Pan American Health Organization reports that over 60% of countries now have regulatory frameworks for standardized blood screening practices, ensuring safety, efficacy, and quality control.

Growing Preventive Healthcare

There is a noticeable shift towards preventive healthcare, with more emphasis on early detection and management of diseases. This trend is driving demand for comprehensive blood screening services, as healthcare providers recognize the importance of proactive measures in improving patient health outcomes.

The UNICEF highlights that preventive screening programs now cover over 200 million individuals annually, reflecting a global shift toward early disease detection.

Blood Screening Market Drivers

Regulatory Framework Enhancements

The Blood Screening Market is significantly influenced by the evolving regulatory landscape. Governments and health authorities are increasingly implementing stringent regulations to ensure the safety and efficacy of blood screening processes. These regulations often mandate comprehensive testing protocols for blood products, thereby driving the demand for advanced screening technologies.

For instance, the introduction of new guidelines for blood safety has led to an uptick in the adoption of automated screening systems. This regulatory push is expected to propel the Blood Screening Market forward, as compliance with these standards necessitates investment in innovative screening solutions.

Expansion of Healthcare Infrastructure

The expansion of healthcare infrastructure, particularly in developing regions, serves as a vital driver for the Blood Screening Market. As countries invest in improving their healthcare systems, the establishment of new hospitals and diagnostic centers increases the demand for blood screening services. This growth is particularly evident in regions where access to healthcare has historically been limited.

The World Health Organization has reported a significant increase in healthcare spending in these areas, which is likely to enhance the availability of blood screening technologies. Consequently, the Blood Screening Market is expected to benefit from this infrastructural development, as more facilities seek to implement comprehensive blood screening programs.

Increasing Prevalence of Infectious Diseases

The rising incidence of infectious diseases is a crucial driver for the Blood Screening Market. As the world witnesses a surge in conditions such as hepatitis, HIV, and other blood-borne pathogens, the demand for effective blood screening solutions intensifies. According to recent estimates, the prevalence of hepatitis C alone affects millions, necessitating robust screening measures.

This trend compels healthcare providers to adopt advanced blood screening technologies to ensure patient safety and effective disease management. Consequently, the Blood Screening Market is likely to experience substantial growth as healthcare systems prioritize the implementation of comprehensive screening protocols to combat these infectious threats.

Technological Innovations in Blood Screening

Technological advancements play a pivotal role in shaping the Blood Screening Market. Innovations such as nucleic acid testing (NAT) and next-generation sequencing (NGS) have revolutionized the accuracy and efficiency of blood screening processes. These technologies enable the detection of pathogens at lower levels, enhancing the safety of blood transfusions.

The market for blood screening technologies is projected to grow significantly, with estimates suggesting a compound annual growth rate (CAGR) of over 8% in the coming years. As healthcare providers increasingly adopt these cutting-edge solutions, the Blood Screening Market is poised for transformative growth, driven by the need for precision and reliability in screening practices.

Rising Awareness of Blood Donation and Screening

The growing awareness surrounding the importance of blood donation and screening is a significant driver for the Blood Screening Market. Educational campaigns and initiatives by health organizations have led to increased public participation in blood donation drives. This heightened awareness not only encourages more individuals to donate blood but also emphasizes the necessity of thorough screening to ensure the safety of the blood supply.

As a result, the demand for blood screening services is expected to rise, with projections indicating a potential increase in screening volumes by 15% over the next few years. This trend underscores the critical role of public health education in bolstering the Blood Screening Market.

Market Segment Insights

By Technology: Nucleic Acid Amplification Test (Largest) vs. Next-Generation Sequencing (Fastest-Growing)

The Blood Screening Market showcases diverse technologies, primarily dominated by Nucleic Acid Amplification Tests (NAAT), which account for a significant portion of the market share. NAAT's effectiveness in detecting pathogens with high sensitivity has made it a preferred choice among healthcare providers. Enzyme-Linked Immunosorbent Assay (ELISA), while important, has a smaller share in comparison, reflecting its specific application niches within blood testing. Meanwhile, Next-Generation Sequencing (NGS) is rapidly gaining traction, attracting considerable attention for its comprehensive and detailed analysis capabilities. The growth trends in this segment indicate a robust upward trajectory, fueled by technological advancements and increasing awareness of infectious diseases. NGS is regarded as the fastest-growing method due to its ability to handle multiplex assays and provide rapid, accurate results. The rising incidence of viruses and a growing emphasis on precision medicine are primary drivers propelling these technologies' acceptance and market expansion in blood screening applications.

Technology: Nucleic Acid Amplification Test (Dominant) vs. Next-Generation Sequencing (Emerging)

Nucleic Acid Amplification Tests (NAAT) represent the dominant technology in the market share due to their unmatched sensitivity and specificity in detecting nucleic acids from pathogens. Their widespread adoption in clinical settings underscores their reliability and efficiency, making them essential for various infectious disease diagnostics. In contrast, Next-Generation Sequencing (NGS) is emerging as a key player in the market, capitalizing on its ability to provide detailed genomic insights. With its growing capacity to perform large-scale genomic analyses at reduced costs and improved turnaround times, NGS is positioned to revolutionize the landscape of blood screening, particularly in identifying complex and rare infections, thereby complementing the established NAAT technology.

By Product & Services: Reagents (Largest) vs. Instruments (Fastest-Growing)

In the Blood Screening Market, 'Reagents' hold the largest share, dominating the landscape with their essential role in various testing procedures. They are critical for the accuracy and reliability of blood screening results, which underscores their importance in clinical settings. In contrast, 'Instruments' are emerging as a significant player, experiencing rapid growth as advancements in technology drive innovation in blood screening solutions. This segment is becoming increasingly vital in enhancing efficiency and accuracy in diagnostic laboratories. The growth trends in the Blood Screening Market are being significantly influenced by the rising prevalence of blood-borne diseases and an increase in awareness regarding early diagnosis. Additionally, technological advancements in instruments, including automation and digitalization, are propelling the expansion of this segment. As healthcare institutions seek to upgrade their capabilities, the demand for innovative blood screening instruments is expected to surge, further solidifying their position in the market for the foreseeable future.

Reagents (Dominant) vs. Instruments (Emerging)

Reagents play a dominant role in the market share due to their essential function in the testing process. They facilitate the detection of various pathogens and markers in blood samples, making them indispensable for accurate diagnostics. The continued reliance on reliable reagents amidst growing health concerns further reinforces their market position. On the other hand, instruments are emerging as a critical component of blood screening solutions. The increasing integration of advanced technologies, such as automated testing systems and point-of-care devices, is enhancing the operational capabilities of diagnostic facilities. This influx of innovative instruments is not only improving turnaround times but also elevating the accuracy of results, thereby positioning them as a rapidly growing segment in the industry.

By End User: Hospitals (Largest) vs. Clinics (Fastest-Growing)

In the Blood Screening Market, the distribution of end users reveals that hospitals hold the largest share, driven by their comprehensive healthcare services and advanced diagnostic capabilities. Clinics, by contrast, are rapidly emerging, adopting blood screening technologies for faster diagnosis and treatment, reflecting a growing healthcare trend that prioritizes patient-centric services. The 'Others' category, which includes laboratories and research facilities, plays a supportive role but lacks the prominence of the primary segments.

End Users: Hospitals (Dominant) vs. Clinics (Emerging)

Hospitals dominate the market share as they are equipped with sophisticated diagnostic tools and are often the primary settings for extensive blood testing. Their established infrastructure facilitates the integration of advanced screening techniques. Conversely, clinics are emerging as significant players, driven by increased patient footfall and the need for quicker, more accessible testing solutions. These smaller, more agile facilities are adapting rapidly to technological advancements, making them appealing alternatives for routine screenings. The increase in preventive healthcare initiatives further strengthens the position of clinics in this dynamic market.

Get more detailed insights about Blood Screening Market

Request Free Sample

Regional Insights

North America : Market Leader in Innovation

North America leads in the Blood Screening Market Size, accounting for over 45% of the global revenue in 2024. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of blood-borne diseases, and stringent regulatory frameworks. The demand for rapid and accurate diagnostic tests is also on the rise, fueled by technological advancements and a growing focus on preventive healthcare.

The United States is the leading country in this market, followed by Canada. Major players like Abbott Laboratories, Thermo Fisher Scientific, and Becton Dickinson are headquartered here, contributing to a competitive landscape. The presence of these key players ensures continuous innovation and development of new screening technologies, enhancing market growth and improving patient outcomes.

Europe : Regulatory Frameworks Drive Growth

Europe Blood Screening Market was valued at USD 1.02 Billion in 2024, making it the second-largest regional market with a 30% share. The region benefits from robust healthcare systems and increasing investments in diagnostic technologies. Regulatory bodies are actively promoting blood safety and screening standards, which further drives market growth. The rising incidence of infectious diseases and the need for early diagnosis are also significant demand drivers in this region.

Germany and the UK are the leading countries in the European blood screening market, with a strong presence of key players like Roche Diagnostics and Siemens Healthineers. The competitive landscape is characterized by collaborations and partnerships among companies to enhance product offerings. The focus on research and development is also prominent, ensuring that Europe remains at the forefront of blood screening innovations.

Asia-Pacific : Rapid Growth and Expansion

Asia-Pacific is witnessing rapid growth in the blood screening market, holding approximately 20% of the global share. The region's expansion is driven by increasing healthcare expenditure, rising awareness of blood-related diseases, and a growing population. Governments are investing in healthcare infrastructure and promoting initiatives for early disease detection, which are significant catalysts for market growth.

China and India are the leading countries in this region, with a burgeoning demand for advanced diagnostic solutions. The competitive landscape is evolving, with both local and international players like Grifols and Bio-Rad Laboratories expanding their presence. The focus on affordable and accessible healthcare solutions is shaping the market dynamics, making Asia-Pacific a key player in the global blood screening landscape.

Middle East and Africa : Untapped Potential in Healthcare

The Middle East and Africa region is gradually emerging in the blood screening market, holding about 5% of the global share. The growth is primarily driven by increasing investments in healthcare infrastructure and rising awareness of blood safety. Governments are implementing policies to enhance healthcare access, which is expected to boost demand for blood screening technologies in the coming years.

Countries like South Africa and the UAE are leading the market, with a growing number of healthcare facilities adopting advanced diagnostic solutions. The competitive landscape is characterized by a mix of local and international players, focusing on tailored solutions to meet regional needs. The presence of key players is gradually increasing, paving the way for future growth in this untapped market.

Key Players and Competitive Insights

The Blood Screening Market is currently characterized by a dynamic competitive landscape, driven by technological advancements, increasing prevalence of blood-related diseases, and a growing emphasis on early diagnosis. Major players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Siemens Healthineers (DE) are strategically positioned to leverage innovation and expand their market presence. Abbott Laboratories (US) focuses on enhancing its diagnostic capabilities through continuous product development, while Roche Diagnostics (CH) emphasizes partnerships to bolster its research and development efforts.

Siemens Healthineers (DE) is investing in digital transformation initiatives, which collectively shape a competitive environment that prioritizes technological superiority and strategic collaborations. Key business tactics within the Blood Screening Market include localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market appears moderately fragmented, with several key players exerting substantial influence. This structure allows for a competitive interplay where innovation and strategic partnerships are pivotal in maintaining market share and driving growth.

In August 2025, Abbott Laboratories (US) announced the launch of a new blood screening platform designed to improve the accuracy and speed of infectious disease detection. This strategic move is likely to enhance Abbott's competitive edge by addressing the increasing demand for rapid diagnostics, thereby positioning the company favorably in a market that values efficiency and reliability. In September 2025, Roche Diagnostics (CH) entered into a collaboration with a leading biotechnology firm to develop next-generation blood screening assays.

This partnership is indicative of Roche's commitment to innovation and suggests a strategic focus on expanding its product portfolio to meet evolving market needs. Such collaborations may enhance Roche's capabilities in delivering cutting-edge diagnostic solutions, further solidifying its market position. In July 2025, Siemens Healthineers (DE) unveiled a new AI-driven analytics tool aimed at optimizing blood screening processes.

This initiative reflects Siemens' strategic emphasis on integrating artificial intelligence into its offerings, potentially revolutionizing how blood screening is conducted. The introduction of AI technologies may not only improve operational efficiencies but also enhance diagnostic accuracy, thereby attracting a broader customer base. As of October 2025, the Blood Screening Market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence.

Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift underscores the importance of adaptability and forward-thinking strategies in navigating the complexities of the market.

Key Companies in the Blood Screening Market include

Industry Developments

June 2021: Grail, an American pharmaceutical and biotechnology company, has announced the release of the Galleri blood screening test, an advanced multi-cancer screening diagnostic that can detect the presence of multiple cancers. This test will assist the company in screening approximately 50 million people after its launch to obtain full FDA approval by 2023.

May 2021: Tzar Labs, a molecular diagnostics company, and Epigeneres Biotechnology have announced the development of cancer tests for early detection. This test, which will be available by the end of 2023, will assist in determining the various stages of the disease. The company's accuracy rates for cancer screening tests are very high, and it has demonstrated results for all forms of cancer.

October 2020: Siemens Healthineers has announced the availability of its laboratory-based total immunoglobulin test1 for identifying SARS-CoV-2 IgM and IgG immunoglobulin in the blood throughout the world. The ability to identify patients who have an adaptive immune response is made possible by the complete antibody test.

Future Outlook

Blood Screening Market Future Outlook

The Blood Screening Market size is projected to reach USD 9.898 Billion by 2035, growing at a CAGR of 10%

New opportunities lie in:

Development of AI-driven diagnostic tools for enhanced accuracy. Expansion of mobile blood screening units in underserved regions. Partnerships with telehealth platforms for remote screening services.

By 2035, the Blood Screening Market is expected to be robust, driven by innovation and strategic partnerships.

Market Segmentation

Blood Screening Market End User Outlook

Hospitals
Clinics
Others

Blood Screening Market Technology Outlook

Nucleic Acid Amplification Test
Enzyme-Linked Immunosorbent Assay
Next-Generation Sequencing

Blood Screening Market Product & Services Outlook

Reagents
Instruments

Report Scope

MARKET SIZE 2024	3.4(USD Billion)
MARKET SIZE 2025	3.747(USD Billion)
MARKET SIZE 2035	9.898(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	10.2% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Becton Dickinson and Company (US), Ortho Clinical Diagnostics (US), Grifols (ES), Bio-Rad Laboratories (US), Hologic (US)
Segments Covered	Technology
Key Market Opportunities	Integration of advanced technologies enhances accuracy and efficiency in the Blood Screening Market.
Key Market Dynamics	Technological advancements and regulatory changes drive innovation and competition in the blood screening market.
Countries Covered	North America, Europe, APAC, South America, MEA

Market Highlights

Blood Screening Companies

FAQs

What is the projected market valuation of the Blood Screening Market by 2035?

The Blood Screening Market is projected to reach approximately 9.898 USD Billion by 2035.

What was the market valuation of the Blood Screening Market in 2024?

In 2024, the Blood Screening Market was valued at 3.4 USD Billion.

What is the expected CAGR for the Blood Screening Market during the forecast period 2025 - 2035?

The expected CAGR for the Blood Screening Market during the forecast period 2025 - 2035 is 10.2%.

Which technology segment is anticipated to show significant growth in the Blood Screening Market?

The Nucleic Acid Amplification Test segment is expected to grow from 1.2 USD Billion in 2024 to 3.5 USD Billion by 2035.

What are the key products and services driving the Blood Screening Market?

Reagents and instruments are key products, with reagents projected to grow from 1.5 USD Billion in 2024 to 4.5 USD Billion by 2035.

Which end-user segment is likely to dominate the Blood Screening Market?

Hospitals are likely to dominate the end-user segment, growing from 1.7 USD Billion in 2024 to 4.8 USD Billion by 2035.

Who are the leading companies in the Blood Screening Market?

Key players in the Blood Screening Market include Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers.

What is the growth outlook for the Enzyme-Linked Immunosorbent Assay segment?

The Enzyme-Linked Immunosorbent Assay segment is projected to increase from 1.0 USD Billion in 2024 to 2.8 USD Billion by 2035.

How does the Next-Generation Sequencing segment perform in the Blood Screening Market?

The Next-Generation Sequencing segment is expected to grow from 1.2 USD Billion in 2024 to 3.6 USD Billion by 2035.

What is the anticipated growth for the Clinics end-user segment in the Blood Screening Market?

The Clinics end-user segment is projected to grow from 1.0 USD Billion in 2024 to 2.8 USD Billion by 2035.

Author

Author

Rahul Gotadki

Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment

Certified Researchers

Customize Report

Research Approach

Secondary Research

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical and transfusion medicine journals, clinical publications, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER), European Medicines Agency (EMA), World Health Organization (WHO) Blood Safety and Availability Programme, US Centers for Disease Control and Prevention (CDC) Division of Healthcare Quality Promotion, Clinical Laboratory Improvement Amendments (CLIA) database, American Association of Blood Banks (AABB), International Society of Blood Transfusion (ISBT), America's Blood Centers, European Centre for Disease Prevention and Control (ECDC), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI/PubMed), and national blood service reports from key markets.

These sources were employed to gather data on the prevalence of infectious diseases (HIV, HBV, HCV, and syphilis), regulatory approval data for nucleic acid amplification tests (NAT) and enzyme-linked immunosorbent assay (ELISA) platforms, clinical safety studies, transfusion-transmitted infection (TTI) screening protocols, and market landscape analysis for reagents, kits, and automated screening instruments. Additionally, blood donation statistics were utilized.

Primary Research

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. In-vitro diagnostic (IVD) manufacturers, blood screening platform developers, and reagent producers were among the supply-side sources, which included CEOs, VPs of Research & Development, global regulatory affairs managers, and commercial directors. Blood bank medical directors, hospital transfusion service managers, hematologists, clinical laboratory directors, infectious disease specialists, and procurement leads from independent blood centers, hospital-based blood banks, and diagnostic laboratories comprised demand-side sources. Market segmentation was validated across NAT, ELISA, and next-generation sequencing technologies; product pipeline timelines for multiplex screening assays were confirmed; and insights on blood donation screening volumes, reimbursement dynamics for transfusion medicine, and adoption patterns of automated molecular platforms were gathered through primary research.

Primary Respondent Breakdown:

• By Designation: C-level Primaries (32%), Director Level (30%), Others (38%)

• By Region: North America (32%), Europe (25%), Asia-Pacific (33%), Rest of World (10%)

Market Size Estimation

The revenue mapping and screening procedure volume analysis across blood banks and transfusion centers were used to derive the global market valuation. The methodology comprised the following:

• Identification of over 50 main manufacturers in North America, Europe, Asia-Pacific, and Latin America who specialize in blood screening technologies

• Product mapping across nucleic acid amplification tests (NAT), enzyme-linked immunosorbent assays (ELISA), next-generation sequencing (NGS), rapid tests, and western blot technologies

• Segment-specific analysis of reagents and kits (recurring revenue) and instruments (capital equipment) in hospital blood banks, independent blood centers, and clinical laboratories

• Examination of the annual revenues that have been reported and modeled for the blood screening and transfusion safety portfolios

• In 2024, the coverage of manufacturers will account for 75-80% of the global market share.

• Segment-specific valuations for infectious disease screening (HIV, HBV, HCV, Zika, syphilis), blood typing, and immunohistochemistry applications are derived through extrapolation using bottom-up (blood donation screening volume × average selling price by country/region) and top-down (manufacturer revenue validation) approaches.